WAM
BMRN icon

Wolverine Asset Management’s BioMarin Pharmaceuticals BMRN Stock Holding History

Wolverine Asset Management’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-61
Closed -$6.31K – 1901
2022
Q4 		$6.31K Sell
61
-781
-93% -$73.3K ﹤0.01% 1719
2022
Q3 		$71K Sell
842
-1,900
-69% -$169K ﹤0.01% 1512
2022
Q2 		$227K Hold
2,742
– – ﹤0.01% 1178
2022
Q1 		$211K Sell
2,742
-2,000
-42% -$167K ﹤0.01% 1154
2021
Q4 		$418K Sell
4,742
-4,509
-49% -$372K ﹤0.01% 1063
2021
Q3 		$715K Sell
9,251
-7,845
-46% -$619K 0.01% 858
2021
Q2 		$1.43M Sell
17,096
-2,615
-13% -$207K 0.01% 525
2021
Q1 		$1.49M Buy
19,711
+10,304
+110% +$842K 0.01% 520
2020
Q4 		$824K Buy
9,407
+3,177
+51% +$252K 0.01% 701
2020
Q3 		$473K Buy
6,230
+5,895
+1,760% +$596K ﹤0.01% 749
2020
Q2 		$41K Buy
+335
New +$33.3K ﹤0.01% 1263
2019
Q3 		– Sell
-2,622
Closed -$224K – 1395
2019
Q2 		$224K Buy
2,622
+2,020
+336% +$173K ﹤0.01% 1017
2019
Q1 		$53K Buy
+602
New +$55.8K ﹤0.01% 1177
2015
Q2 		– Sell
-550
Closed -$68.2K – 1847
2015
Q1 		$68K Sell
550
-2,188
-80% -$232K ﹤0.01% 1186
2014
Q4 		$247K Buy
2,738
+800
+41% +$66.5K ﹤0.01% 867
2014
Q3 		$139K Buy
1,938
+1,700
+714% +$112K ﹤0.01% 1199
2014
Q2 		$14K Buy
+238
New +$14.4K ﹤0.01% 1777

Other funds holding BMRN

Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Wolverine Asset Management's BMRN Position: Q1 2023 in Review

Wolverine Asset Management sold out of BioMarin Pharmaceuticals (BMRN) in Q1 2023, closing a stake of 61 shares — an estimated $6.31K sold.

Wolverine Asset Management first reported a position in BMRN in Q2 2014 and held it in 17 quarters. The position peaked at $1.49M in Q1 2021. 552 funds tracked by Wall St. Rank hold BMRN as of Q1 2023.

  • Wolverine Asset Management reported no remaining BioMarin Pharmaceuticals position as of Q1 2023 after selling out during the quarter.
  • Wolverine Asset Management sold 61 BioMarin Pharmaceuticals shares in Q1 2023, an estimated $6.31K.
  • Wolverine Asset Management first reported a position in BioMarin Pharmaceuticals in Q2 2014 and held it in 17 quarters.
  • Wolverine Asset Management's BioMarin Pharmaceuticals position peaked at $1.49M in Q1 2021.
  • 552 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q1 2023.

Based on Wolverine Asset Management's 13F filing for Q1 2023, filed 8 May 2023.